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Background: In northern Papua New Guinea (PNG), most Plasmodium falciparum isolates proved resistant to
chloroquine (CQ) in vitro between 2005 and 2007, and there was near-fixation of pfcrt K76T, pfdhfr C59R/S108N and
pfmdr1 N86Y. To determine whether the subsequent introduction of artemisinin combination therapy (ACT) and reduced
CQ-sulphadoxine-pyrimethamine pressure had attenuated parasite drug susceptibility and resistance-associated mutations,
these parameters were re-assessed between 2011 and 2013.
Methods: A validated fluorescence-based assay was used to assess growth inhibition of 52 P. falciparum isolates from
children in a clinical trial in Madang Province. Responses to CQ, lumefantrine, piperaquine, naphthoquine, pyronaridine,
artesunate, dihydroartemisinin, artemether were assessed. Molecular resistance markers were detected using a multiplex
PCR ligase detection reaction fluorescent microsphere assay.
Results: CQ resistance (in vitro concentration required for 50% parasite growth inhibition (IC50) >100 nM) was present
in 19% of isolates. All piperaquine and naphthoquine IC50s were <100 nM and those for lumefantrine, pyronaridine
and the artemisinin derivatives were in low nM ranges. Factor analysis of IC50s showed three groupings (lumefantrine;
CQ, piperaquine, naphthoquine; pyronaridine, dihydroartemisinin, artemether, artesunate). Most isolates (96%) were
monoclonal pfcrt K76T (SVMNT) mutants and most (86%) contained pfmdr1 N86Y (YYSND). No wild-type pfdhfr was found
but most isolates contained wild-type (SAKAA) pfdhps. Compared with 2005–2007, the geometric mean (95% CI) CQ IC50
was lower (87 (71–107) vs 167 (141–197) nM) and there had been no change in the prevalence of pfcrt K76T or pfmdr1
mutations. There were fewer isolates of the pfdhps (SAKAA) wild-type (60 vs 100%) and pfdhfr mutations persisted.
Conclusions: Reflecting less drug pressure, in vitro CQ sensitivity appears to be improving in Madang Province despite
continued near-fixation of pfcrt K76T and pfmdr1 mutations. Temporal changes in IC50s for other anti-malarial drugs were
inconsistent but susceptibility was preserved. Retention or increases in pfdhfr and pfdhps mutations reflect continued use
of sulphadoxine-pyrimethamine in the study area including through paediatric intermittent preventive treatment. The
susceptibility of local isolates to lumefantrine may be unrelated to those of other ACT partner drugs.
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Resistance of Plasmodium falciparum to anti-malarial drugs
in Papua New Guinea (PNG) began with chloroquine (CQ)
in the 1970s [1] and has since extended to amodiaquine [2]
and sulphadoxine-pyrimethamine (SP) [3]. Because of this
trend, together with efficacy data from a large-scale, multi-
arm, treatment trial conducted in coastal PNG from 2005
to 2007 [4] and World Health Organization management
guidelines at the time [5], artemisinin combination therapy
(ACT) was introduced nationally as recommended therapy
for uncomplicated malaria in 2010 [6]. Artemether (AM)
plus lumefantrine (LM) is currently first-line and dihydroar-
temisinin (DHA) plus piperaquine (PQ) second-line treat-
ment in PNG, but artemisinin plus naphthoquine (NQ) is
also available in the private sector [7]. Resistance to artemi-
sinin derivatives has, however, emerged in recent years in
Southeast Asia [8], and is a concern for countries such as
PNG in which ACT is now widely used.
Regular testing using economical, robust and sensitive
in vitro anti-malarial drug susceptibility assays is an inte-
gral part of the surveillance for parasite resistance [9].
Of the different methods currently available, those based
on fluorescence measurements of parasite growth using
inexpensive intercalating DNA stains such as Sybr Green
and Pico Green have proved efficient and inexpensive
without loss of sensitivity [10,11]. Additional insight into
mechanisms of resistance is provided by detection of
single nucleotide polymorphisms in parasite genes deter-
mining drug response [12], including mutations in the P.
falciparum CQ transporter (pfcrt), multidrug resistance
1 (pfmdr1), dihydrofolate reductase (pfdhfr), and dihy-
dropteroate synthetase (pfdhps) genes.
The most recent parasite drug resistance data from
PNG were collected as part of the comparative interven-
tion trial conducted in coastal Madang and East Sepik
Provinces between 2005 and 2007 [13,14]. Most of the
isolates tested proved resistant to CQ in vitro but not to
other ACT partner drugs or to the artemisinin derivatives
themselves [13]. Consistent with this finding and previous
heavy 4-aminoquinoline/SP use, there was near-fixation of
pfcrt K76T, pfdhfr C59R and S108N, and pfmdr1 N86Y
alleles, while multiple mutations were frequent [14].
To determine whether there has been any recent change
in P. falciparum drug resistance in the north coastal PNG
area, the in vitro susceptibility of local P. falciparum
isolates collected between 2011 and 2013 to artemisinin
derivatives and ACT partner drugs were re-assessed, and
the prevalence of drug resistance markers in the same
parasite strains re-examined.
Methods
Study sites, patients and ethical approval
Venous blood samples were obtained from 52 children
aged six months to five years with an uncomplicated P.falciparum mono-infection at a parasitaemia >0.5% who
were recruited at Mugil (n = 43) and Alexishafen (n = 9)
health centres in Madang Province to a randomized,
comparative, efficacy trial of the ACT AM-LM and
artemisinin-NQ (Australian New Zealand Clinical Trials
Registry ACTRN12610000913077) [15]. The study received
ethical approval from the Medical Research Advisory Com-
mittee of the PNG Department of Health (MRAC #10.39).
In all cases, informed consent was obtained from the
parents or legal guardians before recruitment and blood
sampling.
Drug susceptibility assays
A Sybr Green fluorescence assay was used to assess drug
susceptibility. All assays were carried out at the PNG
Institute of Medical Research in Madang. The method-
ology used, a modified version of that first described by
Smilkstein et al. [11], has been previously validated against
tritium hypoxanthine incorporation, Pf lactate dehydro-
genase (PfLDH), light microscopic schizont maturation,
and flow cytometry-based drug susceptibility assays using
the laboratory-adapted parasite strains 3D7, E8B and
W2 [16]. For the present series of experiments, the 3D7
strain was used as reference with a mean CQ in vitro
concentration required for 50% parasite growth inhib-
ition (IC50) value of 14.3 nM. This compares with IC50
values of 18–20 nM for tritiated hypoxanthine isotopic
assay and 23–33 nM for PfLDH assay using this strain
in our laboratories at Fremantle Hospital in Australia
(unpublished observations).
The anti-malarial compounds used in this assay were
purchased from Sigma-Aldrich, St Louis, MI, USA (CQ
diphosphate), Santa Cruz Biotechnologies, Santa Cruz,
CA, USA (pyronaridine (PY) tetraphosphate), Hubei On-
ward Bio Development Co Ltd, Enshi City, Hubei, China
(DHA, artesunate (AS), AM, LM) or kindly donated by
Mangalam Pty Ltd, Bangalore, India (PQ phosphate and
NQ phosphate). Solutions of 10 mM concentration were
prepared for each drug in an appropriate solvent (CQ,
PQ and PY in deionized water; AM in methanol; NQ in
50% v/v ethanol; LM in 1:1:1 v/v linoleic acid/Tween 80/
ethanol; DHA in 70% v/v ethanol; AS in ethanol). These
solutions were further diluted to a stock 1 mM concen-
tration in deionized water. After sterile filtration, stock
solutions were aliquoted into airtight microcentrifuge
tubes and stored at −20°C. A fresh aliquot was used for
each assay.
Red blood cells from slide-positive children were washed
three times in standard RPMI 1640-based malaria cell cul-
ture medium [17] and, if necessary, diluted to 0.5-1.0%
parasitaemia with red blood cells from a malaria-naïve
donor of blood type O Rhesus negative. The culture
medium consisted of RPMI 1640 HEPES (Sigma Aldrich,
St Louis, MO) supplemented with 92.6 mg/L L-glutamine
Figure 1 50% inhibitory concentrations (IC50) for the anti-malarial
compounds investigated in the present study. Chloroquine (CQ),
piperaquine (PQ), naphthoquine (NQ), pyronaridine (PY), lumefantrine
(LM), dihydroartemisinin (DHA), artesunate (AS) artemether (AM).
Panel A shows the logarithmic means and 95% CIs and Panel B shows
measurements for single isolates.
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(Sigma Aldrich, St Louis, MO), 50 mg/L hypoxanthine
(Sigma Aldrich, St Louis, MO) and 0.5% w/v Albumax II
lipid rich BSA (Life Technologies, Mulgrave, Victoria,
Australia) [16]. Drug dilutions were set up in 96-well
plates in triplicate, with eight dilutions for each drug. The
haematocrit was set at 1% and the liquid volume per well
was 200 μL. The assay plates were incubated for 48 hr in a
candle jar using the method of Trager and Jensen [18],
after which 50 μL of a red cell lysis buffer/Sybr green
(Invitrogen, Carlsbad, CA, USA) mixture were added to
each well. The plate was incubated for 15 min in the dark.
Fluorescence was read on a microplate reader (Fluostar
Optima, BMG Labtec, Offenburg, Germany) equipped
with a 484 nm excitation filter and a 520 nm absorbance
filter.
Molecular analysis
Parasite isolates where tested for genetic markers asso-
ciated with drug resistance using a multiplex polymer-
ase chain reaction ligase detection reaction fluorescent
microsphere assay (PCR-LDR-FMA) assay as previously
described [14,19]. In brief, PCR-LDR-FMA was per-
formed using established primer sequences to detect
single nucleotide polymorphisms in the known resistance
loci of pfdhfr (codons 51, 58, 108, 164), pfdhps (codons
436–437, 540, 581, 613), pfcrt (codons 72–76) and pfmdr1
(codons 86, 184, 1034, 1042, 1246). Fluorescent prod-
ucts were detected using a Bio-Plex analyzer (Bio-Rad,
Hercules, CA, USA). Data analysis was conducted as
described previously [20,21].
Data analysis
Concentrations of anti-malarial drugs for each isolate and
anti-malarial were log-transformed and the fluorescence
values were normalized such that the smallest value in
each dataset represented 0 and the largest value (drug-
free control) unity. The dose–response curve Y = 100/
(1 + 10k (logIC50-logX)) was then fitted to each dataset,
where Y corresponds to the percentage of growth at drug
concentration X, and k is the Hill slope. For calculations
of means and 95% confidence intervals (CI) as well as for
analysis of associations between pairs of different anti-
malarial drugs, the log10 IC50 values were used as these
were normally distributed by Kolmogorov-Smirnov test.
Associations between IC50 values were determined using
Pearson’s correlation coefficient, and significant pairwise
correlations (P < 0.05) were considered moderate for
0.3 ≤ r ≤0.50 or strong for r >0.5.
Factor analysis was conducted after testing the cross-
correlation matrix for sphericity using Bartlett’s Test and
using the Kaiser-Maier-Olkin statistic to determine the
appropriateness of the data for this analysis. The distri-
bution of the Eigenvalues of the cross-correlation matrixindicated that factoring into two components was the
most appropriate approach. Since it was hypothesized
that the underlying factors relate to the mechanisms of
drug action and are thus related to each other, a non-
orthogonal (direct-oblimin) rotation was applied to the
solution.
Results
In vitro drug susceptibility measurements
From a total of 416 drug assays (52 isolates and 8 drugs),
379 (91.1%) provided a valid dose–response curve that
could be used for analysis. Numbers of successful assays
per drug were 47 (NQ), 44 (LM), 50 (DHA), 50 (AS), 48
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of the parasite isolates to the panel of anti-malarial drugs
used in the present study are summarized in Figure 1. CQ
resistance (IC50 > 100 nM [22,23]) was present in nine out
of 48 isolates (19%). For alternative resistance thresholds
of 87 nM, 70 nM and 25 nM as recommended by other
authors [24-26], the percentages of resistant strains were
26, 42 and 88%, respectively. Although there is no recom-
mended threshold for PQ or NQ, 100 nM has been
suggested for PQ and may also be appropriate for NQ [27].
All isolates had an IC50 value for PQ and NQ <100 nM, but
two strains had IC50 values that were close to this value
(85 nM for PQ in one case and 96 nM for NQ in the
other). Logarithmic mean IC50 values and their 95% CIs
were 87 (71–107) nM for CQ, 21.0 (16.9-26.1) nM for PQ,
4.2 (3.1-5.8) nM for NQ, 8.0 (6.0-10.6) nM for PY, 1.5
(1.1-2.1) nM for LM, 5.2 (4.2-6.5) nM for DHA, 6.1
(4.9-7.6) nM for AS and 5.7 (4.2-7.9) nM for AM.
Table 1 shows the cross-correlation analysis for each
pair of anti-malarial drugs. The strongest correlations
were observed between the IC50 values for i) CQ, PQ,
NQ, and PY (0.31 < r < 0.55) with an exception being that
between CQ and PY (P > 0.05), and ii) between DHA,
AM, AS, and PY (0.45 < r < 0.66) with an exception beingTable 1 Cross-correlation (Pearson’s r) between growth inhib
paired IC50s analysed
Chloroquine Naphthoquine Piperaquine
Naphthoquine
r 0.35*
P 0.020
n 45
Piperaquine
r 0.44** 0.55**
P 0.002 <0.001
n 45 44
Pyronaridine
r 0.19 0.49** 0.31*
P 0.23 0.001 0.042
n 43 44 43
Lumefantrine
r −0.08 0.21 −0.03
P 0.62 0.18 0.86
n 42 42 42
Dihydro-artemisinin
r 0.27 0.20 0.33*
P 0.065 0.18 0.026
n 48 47 47
Artesunate
r 0.28 0.38** 0.27
P 0.060 0.009 0.067
n 47 46 47
Artemether
r 0.24 0.37* 0.29*
P 0.11 0.012 0.048
n 46 46 46
The data were log-transformed before analysis. The symbols * and ** indicate P < 0that between PY and AM (P > 0.05). The IC50 values for
LM showed no significant correlations with those of
any of the other drugs. Factor analysis indicated two
underlying components, which may explain most of the
variation in drug responses (see Figure 2). Within this
two-component space, the eight drugs clustered into
three distinct groups (LM on its own; CQ, PQ and NQ;
PY, DHA, AM, and AS).
Drug resistance markers and their association with
in vitro drug susceptibility
Most isolates (96%) were monoclonal pfcrt K76T mutants
of haplotype SVMNT (codons 72 to 76). One isolate
contained a mix of CVMNK (wild-type) and SVMNT
(mutant). In only one isolate was CVMNK (wild-type)
detected as the only clone. This isolate exhibited an
IC50 of 12.1 nM against CQ, which was the lowest in
IC50 for CQ found in the study. The polyclonal
CVMNK/SVMNT isolate exhibited a CQ IC50 of 30.0
nM, which was also amongst the lowest values deter-
mined in the present study.
Two mutant haplotypes of pfmdr1 were identified, the
most prevalent being the YYSND type associated with
CQ resistance (86% of isolates, N86Y mutation). Theition to anti-malarial drugs where n is the number of
Pyronaridine Lumefantrine Dihydro-artemisinin Artesunate
0.13
0.40
42
0.47** 0.11
0.001 0.48
45 44
0.45** 0.24 0.66**
0.002 0.12 <0.001
45 44 49
0.29 0.04 0.49** 0.64**
0.053 0.78 <0.001 <0.001
45 44 48 48
.05 and P < 0.01, respectively.
Figure 2 Factor analysis of IC50 values. Kaiser-Maier-Olkin (KMO)
statistics and Bartlett’s Test for sphericity indicated the appropriateness
of the data for factor analysis (KMO statistic: 0.62, Bartlett’s test
p-value: <0.0001). The distribution of the Eigenvalues indicated that a
separation into two components was most appropriate. Within the
two-component space, three distinct clusters of drugs were
observed (1: lumefantrine (LM) 2: chloroquine (CQ), piperaquine
(PQ), naphthoquine (NQ); 3: pyronaridine (PY), artesunate (AS),
dihydroartemisinin (DHA), artemether (AM)).
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mutation). The wild-type NYSND occurred in only 9%
of isolates. The presence of NYSND was associated with
reduced CQ IC50 values (P < 0.05, see Table 2).
No wild-type pfdhfr was found in the isolates studied.
All isolates carried the C59R mutation and the S108N
mutation (with absence of mutation at codons 51 and
164, Figure 3). Among them, 13% of isolates were
polyclonal with the S108T mutation detected as well
(haplotype NRTI). The SAKAA wild-type haplotype of the
pfdhps gene was found as the only haplotype in 60% of all
isolates and in a further 9% in polyclonal infections. The
SGKAA and the SGEAA mutant haplotypes occurred in 9
and 14% as monoclonal infections, respectively, and in a
further 9% of polyclonal infections. An additional haplo-
type FGEAA was found in 6% of infections, mixed with
the SGEAA haplotype.
Comparison of the present findings with those of similar
surveillance in 2005–2007
The geometric mean and 95% CIs for parasite isolates
obtained from children with uncomplicated malaria in a
study carried out in Madang and East Sepik Provinces
between 2005 and 2007, as well as the present drug
susceptibility data, are shown in Table 3 [13]. The
method used in the earlier study was the PfLDH assay[28]. The IC50 values were lower for the present isolates
than those obtained an average of six years earlier for
CQ, NQ and LM, but higher for PQ and DHA.
The P. falciparum polymorphisms associated with anti-
malarial drug resistance for the isolates obtained between
2005 and 2007 [14], as well as those of the present study,
are shown graphically in Figure 3. There had been no
change in the near-fixation of pfcrt K76T in the six years
between studies and the prevalence of pfmdr1 mutations
was also similar. The NRTI haplotype was not reported in
the previous study using the same methodology [14]
but it was detected by the present genotyping. The
pfdhps wild-type gene (SAKAA) was found as the only
haplotype in 60% of all isolates and in a further 9% of
polyclonal infections, a lower prevalence than the ~100%
reported previously [14].
Discussion
The present data demonstrate that there have been
changes in the drug resistance characteristics of parasite
isolates collected between 2005–2007 and 2011–2013
from areas of north coastal PNG with intense malaria
transmission. Although a different methodology was used
to assess in vitro sensitivity in the present study, and
notwithstanding limitations in assigning thresholds for
in vitro drug sensitivity [29], more strains appeared CQ-
sensitive than in 2005–2007 [13,14] despite the majority
retaining the mutant pfcrt K76T allele over time. There
were also apparent temporal reductions in the IC50s of
LM and NQ, while those for PQ and DHA increased
albeit still within relatively low nM ranges. The proportion
of parasites carrying the wild-type pfdhps gene had fallen
over time and more mutations had appeared in pfdhps in
the 2011–2013 isolates, consistent with continued use of
SP in the study area. Factor analysis suggested that the
in vitro susceptibilities of PNG P. falciparum strains to
LM and PY may be unrelated to those of other long
half-life ACT partner drugs, with the IC50 of PY clustering
with those of the artemisinin derivatives. Interpretation of
the present and previous data needs to take into account
several factors. These comprise i) temporal changes in
anti-malarial drug use in the study areas, ii) potential
effects of the introduction of non-pharmacological
strategies to reduce malaria transmission, and iii) differ-
ences in assay methodology between 2005–2007 and
2011–2013.
Recommendations regarding replacement of regimens
based on CQ and SP by ACT for treatment of uncompli-
cated malaria in PNG children were implemented in
2010 [6], but translation of this policy into practice has
been slow. In addition, the use of CQ and SP as first-line
intermittent preventive therapy (IPT) in pregnancy has
continued, and an IPT trial in infants involving SP was
conducted in the Mugil area (from where most of the
Table 2 Associations between Plasmodium falciparum genetic mutations and IC50 values for chloroquine (CQ),
piperaquine (PQ), naphthoquine (NQ), pyronaridine (PY), lumefantrine (LM), dihydroartemisinin (DHA), artesunate (AS)
artemether (AM)
pfcrt Wild-type (CVMNK) Mixed Mutant
CQ 12 (n = 1) 30 (n = 1) 96 (79–117) (n = 39)
NQ 5.9 (n = 1) 0.6 (n = 1) 4.3 (3.9-5.9) (n = 37)
PQ 13.0 (n = 1) 11.4 (n = 1) 21.3 (16.8-27.0) (n = 39)
PY 32.5 (n = 1) 2.2 (n = 1) 7.4 (5.5-9.8) (n = 36)
LM 17.8 (n = 1) 2.0 (n = 1) 1.5 (1.0-2.0) (n = 34)
DHA 6.6 (n = 1) 3.8 (n = 1) 5.0 (3.0-6.4) (n = 40)
AS 6.6 (n = 1)) 2.1 (n = 1) 5.4 (3.7-8.0) (n = 38)
AM 6.4 (n = 1) 3.3 (n = 1) 6.3 (5.0-7.8) (n = 39)
dhps Wild-type (SAKAA) Mixed Mutant
CQ 84 (59–118) (n = 17) 192 (39–944) (n = 3) 72 (41–124) (n = 8)
NQ 4.6 (2.4-8.8) (n = 16) 7.2 (3.1-16.4) (n = 3) 3.4 (1.7-6.8) (n = 8)
PQ 18.6 (12.4-27.9) (n = 17) 31.9 (19.7-51.7) (n = 3) 17.8 (9.2-34.2) (n = 8)
PY 8.0 (4.7-13.6) (n = 17) 9.0 (3.1-26.3) (n = 3) 7.3 (2.8-18.9) (n = 7)
LM 2.1 (1.0-4.4) (n = 16) 1.5 (1.5-1.6) (n = 3) 1.3 (0.9-2.0) (n = 6)
DHA 4.5 (3.0-6.7) (n = 17) 7.6 (0.8-72.6) (n = 3) 7.0 (3.2-15.1) (n = 8)
AS 6.2 (4.2-9.2) (n = 17) 8.0 (5.6-11.5) (n = 3) 6.9 (2.8-16.9) (n = 8)
AM 6.2 (4.2-9.2) (n = 17) 6.9 (4.7 -10.2) (n = 3) 5.7 (3.4-9.4) (n = 8)
dhfr Wild-type (NCSI) Mixed# Mutant
CQ - 161 (22–1195) (n = 3) 89 (71–112) (n = 33)
NQ - 4.7 (2.0-10.1) (n = 3) 4.1 (2.8-5.9) (n = 32)
PQ - 17.39 (2.7-113.3) (n = 3) 20.5 (15.9-26.5) (n = 34)
PY - 3.9 (0.6-27.4) (n = 3) 7.7 (5.5-10.7) (n = 32)
LM - 1.2 (0.5-2.7) (n = 3) 1.6 (1.0-2.4) (n = 30)
DHA - 8.0 (0.8-72.3) (n = 3) 4.9 (3.7-6.5) (n = 34)
AS - 7.4 (4.1-13.4) (n = 3) 5.7 (3.8-8.5) (n = 33)
AM - 7.5 (2.2-26) (n = 3) 6.2 (4.8-7.9) (n = 34)
pfmdr1 Wild-type (NYSND) Mixed Mutant
CQ - 39 (12–125) (n = 3) 96 (77–122) (n = 33)*
NQ - 1.5 (1.5-1.5) (n = 2) 4.4 (3.1-6.2) (n = 32)
PQ - 11.5 (6.6-20.1) (n = 3) 20.9 (16.2-27.1) (n = 34)
PY - 2.2 (0.0-217.1) (n = 2) 7.8 (5.7-10.9) (n = 32)
LM - 0.8 (0.2-2.8) (n = 3) 1.7 (1.1-2.5) (n = 30)
DHA - 4.7 (2.9-7.6) (n = 3) 5.1 (3.8-6.8) (n = 34)
AS - 3.8 (0.5-30.6) (n = 3) 5.8 (3.9-8.7) (n = 33)
AM - 5.9 (2.5-13.6) (n = 3) 6.4 (5.0-8.2) (n = 34)
Values are given as geometric mean (95% confidence interval [where applicable]) with (number of paired observations).
*P < 0.05 by Mann–Whitney U test; #‘Mixed’ corresponds to a mix of NRNI and NRTI, since no wild types were found.
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[30]. Therefore, CQ-SP drug pressure had been reduced,
but not eliminated, over a period of two to three years
leading up to isolate collection in the study area.
The dynamics governing repopulation by CQ-sensitive
strains in areas in which CQ treatment pressure has been
removed completely are not well understood, but thetime-scale is probably approaching a decade [24,31,32].
The fact that the present isolates were collected after a
short period of incomplete removal of CQ-SP pressure is
reflected in the present molecular analyses which showed
no reduction or an increase in parasites carrying genetic
markers that correlate with CQ-SP resistance. However,
CQ resistance mutations are frequently found in isolates
Figure 3 Prevalence of drug resistance-associated gene
mutations in parasite isolates from north coastal PNG. Numbers
in parentheses denote the number of samples that resulted in
interpretable genotyping results. Panel A shows data collected in
the present study and panel B shows data collected between 2005
and 2007 [14]. Percentages of wild-type genotypes (■), mutants (□)
and mixed infections (grey square) are shown.
Table 3 Comparison of IC50 values determined using the
PfLDH assay in 2006 in the same population and the Sybr
Green assays in 2012
2005-2007 2011-2013 P-value
Drug n IC50 n IC50
Chloroquine 63 167 (141–197) 48 87 (71–106) <0.001
Piperaquine 57 11.7 (10.2-13.4) 47 21.1 (17–26) <0.001
Naphthoquine 41 7.0 (5.5-8.8) 44 4.2 (3.1-5.8) 0.015
Lumefantrine 25 2.4 (1.8-3.1) 47 1.5 (1.1-2.1) 0.075
Dihydroartemisinin 30 2.1 (1.5-2.9) 50 5.2 (4.2-6.5) <0.001
Data are geometric mean and (95% CI) and P-values are two-tailed from
Student’s t-test.
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also evidence that CQ IC50 values can fall relatively
quickly (within a few years) after reduction in drug
pressure [34,35].
The introduction of long-lasting insecticide-impregnated
bed nets (LLINs), such as was started on a large scale in
PNG in 2004 [36], could theoretically also attenuate drug
pressure by reducing malaria transmission. The evidence
for this effect on molecular resistance markers in studies
from sub-Saharan Africa is conflicting [37,38]. However,
these studies were relatively short-term compared with the
time needed for re-establishment of full sensitivity after
drug withdrawal [24,31,32] and no in vitro susceptibility
data were presented. It remains possible that increasing
LLIN use in coastal PNG between 2005–2007 and
2011–2013, together with the partial replacement of
CQ-SP by ACT, both contributed to the lower IC50 for
CQ in the present study.
There is no accepted standardized protocol for deter-
mining in vitro anti-malarial drug susceptibilities and the
results may differ according to the methodology employed.
There is evidence that the PfLDH assay generates higher
IC50 values than other methodologies including the Sybr
Green assay used in the present study [16,39,40]. However,
the reported differences are typically modest (typically
10–30 nM across a range of IC50 values, as seen with our
own data for the 3D7 strain) compared with the substan-
tial reduction in CQ IC50 observed between 2005–2007
and 2011–2013. The increase in PQ IC50 over time in
north coastal PNG might appear paradoxical given than
CQ and PQ susceptibility have both been considered to
reflect pfcrt mutations [41]. Nevertheless, not all studies
show this relationship [42], while the PQ IC50 values in
both time periods were both well below the conventional
100 nM cut-point for resistance in all but one isolate in
the present study. The small temporal increase in DHA
IC50 may also be of no clinical significance given that the
IC50 value in all isolates was in the very low nM range.
Standard drug susceptibility assays do not detect early
stage artemisinin resistance defined by a slow parasite
clearance time for which there is now a molecular marker
[43], but the isolates were obtained between 2011 and
2013 from patients in a clinical trial [15] in which there
was no evidence of longer parasite clearance times after
AM-LM than in the equivalent trial conducted from 2005
to 2007 [4].
Several studies have shown moderate to strong corre-
lations between in vitro parasite responses to CQ and
PY [44,45] while in others, including the present study,
there has been no such association [46,47]. The future of
PY-containing ACT is uncertain because of hepatotox-
icity [48]. However, it does not appear to exhibit cross-
resistance with CQ in the present parasite isolates, which
would be an advantage if PY-based ACT became available
Koleala et al. Malaria Journal  (2015) 14:37 Page 8 of 9for repeated use in PNG. The present data confirm the
moderate associations between CQ, PQ and NQ which
were also observed previously in north coastal PNG
[13]. Although the IC50s for the latter two compounds
are relatively low, their significant association with CQ
susceptibility may have implications for the longevity of
ACT formulations incorporating them. The lack of cluster-
ing of LM susceptibility with other longer half-life anti-
malarial drugs suggests that it may have an independent
mechanism of action. As has been done by other groups
[49-51], we included the three artemisinin drugs in com-
mon clinical use, even though DHA is the active metabolite
of both AS and AM in vivo, since there is evidence that
their activity against P. falciparum in vitro is not uniform
[52]. Consistent with this latter observation, the association
between AM and DHA was only moderate while those
between AS and both AM and DHA were the strongest
observed.
Conclusion
Although the prevalence of molecular markers of anti-
malarial drug resistance has not fallen in north coastal
PNG over the six years between the present study and a
previous cross-sectional survey, CQ susceptibility has
increased even allowing for different methods of in vitro
parasite drug sensitivity testing. This may reflect attenu-
ation of drug pressure through changes in national treat-
ment policy and the roll-out of LLINs in the study areas.
Although there are no parasite strains showing definite
in vitro resistance to PQ and NQ, the association of PQ
and CQ IC50s suggests that future susceptibility testing
should include these ACT partner drugs which are cur-
rently available in PNG as alternatives to LM. Since LM
drug susceptibility appears independent of other available
and potential ACT partner drugs, the use of AM-LM as
first-line treatment of uncomplicated malaria in PNG may
not lead to clinically significant cross-resistance.
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